Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2017 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member

SAN DIEGO, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the appointment of William R. LaRue as an additional independent member to the Conatus Board...
February 06, 2017 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus to Present at BIO CEO & Investor Conference

SAN DIEGO, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at the...
February 02, 2017 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management

SAN DIEGO , Feb. 02, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today the promotion of Daniel L. Ripley to Senior Vice President, Business Development,...
December 19, 2016 16:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan

- Conference Call and Webcast Presentation at 5:30 p.m. ET Today - - Continuing Initial Focus on NASH Cirrhosis with Parallel Development in NASH Fibrosis - - Full Funding in Position for Remaining...
November 14, 2016 08:00 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

- Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores - - Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models -...
November 09, 2016 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Present at Stifel 2016 Healthcare Conference

SAN DIEGO, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at...
November 08, 2016 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports Third Quarter 2016 Financial Results and Program Updates

SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
November 03, 2016 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the initiation of ENCORE-PH (PH for Portal Hypertension), a randomized, double-blind,...
November 01, 2016 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report Third Quarter 2016 Financial Results

SAN DIEGO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat...
October 03, 2016 16:11 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting

Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models SAN...